Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Inactive · Last trade price on Jan 23, 2024

Company Description

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.

It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency.

The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.

In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema.

The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, United Kingdom.

As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd.

Orchard Therapeutics plc
Orchard Therapeutics logo
CountryUnited Kingdom
Founded2015
IPO DateOct 31, 2018
IndustryBiotechnology
SectorHealthcare
Employees166
CEOHubert Gaspar

Contact Details

Address:
245 Hammersmith Road
London, X0 W6 8PW
United Kingdom
Phone44 20 3 808 8286
Websiteorchard-tx.com

Stock Details

Ticker SymbolORTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001748907
CUSIP Number68570P101
ISIN NumberUS68570P1012
SIC Code2836

Key Executives

NamePosition
Dr. Hubert Baburaj Gaspar M.D., Ph.D.Chief Executive Officer, Member of Scientific Advisory Board and Executive Director
Frank Edward ThomasPresident and Chief Operating Officer
Dr. Nicoletta Loggia Ph.D., R.Ph.Chief Technical Officer
Dr. Fulvio Mavilio Ph.D.Chief Scientific Officer
Renee T. LeckHead of Investor Relations
Benjamin NavonDirector of Corporate Communications
John CerioChief Human Resource Officer
Robin KenselaarSenior Vice President and GM of EMEA Commercial Operations
Braden ParkerChief Commercial Officer
Dr. Leslie Meltzer Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jan 24, 2024POS AMPost-Effective amendments for registration statement
Jan 24, 2024POS AMPost-Effective amendments for registration statement
Jan 24, 20248-KCurrent Report
Jan 24, 202425-NSEFiling